Sixth Element Capital is a firm specializing in early stage investment.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Sixth Element Capital is currently managing its first fund: the £70m CRT Pioneer Fund (CPF) to create the future of cancer therapy and diagnosis.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2021 | NeoPhore | Series B | 0 |
1/2017 | Macrophage Pharma | Series A | 0 |
9/2018 | Azeria Therapeutics | Series A | 0 |
1/2023 | NeoPhore | Series B | 0 |
6/2018 | AdoRx Therapeutics | Series A | 0 |
9/2016 | Achilles Therapeutics | Seed Round | 0 |
11/2019 | Azeria Therapeutics | Series B | 0 |
11/2017 | NeoPhore | Venture Round | 0 |
3/2021 | NeoPhore | Series B | 0 |
11/2019 | Azeria Therapeutics | Series B | 0 |
9/2018 | Azeria Therapeutics | Series A | 0 |
6/2018 | AdoRx Therapeutics | Series A | 0 |
11/2017 | NeoPhore | Venture Round | 0 |
1/2017 | Macrophage Pharma | Series A | 0 |
9/2016 | Achilles Therapeutics | Seed Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|